(Q53668818)

17 May 2018

title

Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? (English)

1 reference

17 May 2018

author name string

Stefan Ehlers

series ordinal

1

1 reference

17 May 2018

language of work or name

English

0 references

publication date

1 August 2005

1 reference

17 May 2018

Clinical Infectious Diseases

published in

1 reference

17 May 2018

volume

41 Suppl 3

1 reference

17 May 2018

page(s)

S199-203

1 reference

17 May 2018

The therapeutic potential of TNF-alpha blockade in rheumatoid arthritis

cites work

1 reference

Biologic therapies in the spondyloarthritis: new opportunities, new challenges

21 January 2018

1 reference

Biological functions of tumor necrosis factor cytokines and their receptors

21 January 2018

1 reference

Tumor necrosis factor signaling.

21 January 2018

1 reference

Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists

21 January 2018

1 reference

Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.

21 January 2018

1 reference

Infliximab treatment of sarcoidosis

21 January 2018

1 reference

Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis

21 January 2018

1 reference

Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept

21 January 2018

1 reference

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis

21 January 2018

1 reference

TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection

21 January 2018

1 reference

The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection

21 January 2018

1 reference

TNF-alpha controls intracellular mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-independent pathways

21 January 2018

1 reference

Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology

21 January 2018

1 reference

Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice

21 January 2018

1 reference

Granulomatous infectious diseases associated with tumor necrosis factor antagonists

21 January 2018

1 reference

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.

21 January 2018

1 reference

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report

21 January 2018

1 reference

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents

21 January 2018

1 reference

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept

21 January 2018

1 reference

Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions

21 January 2018

1 reference

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

21 January 2018

1 reference

The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor

21 January 2018

1 reference

Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guérin infection in the absence of secreted TNF and lymphotoxin-alpha.

21 January 2018

1 reference

Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/429998

1 reference

17 May 2018

PubMed ID

15983900

1 reference

17 May 2018